Abstract: The present invention relates to the field of medicine. More specifically, the present invention relates to compounds that are sigma-1 receptor agonists and their use for the treatment of central nervous system disorders, including cognitive or neurodegenerative disorders, such as Alzheimer's disease, Parkinson's disease, Huntington's disease, Amyotrophic lateral sclerosis, and multiple sclerosis.

Abstract: The present invention relates to the field of medicine. More specifically, the present invention relates to compounds that are sigma-1 receptor agonists and their use for the treatment of central nervous system disorders, including cognitive or neurodegenerative disorders, such as Alzheimer's disease, Parkinson's disease, Huntington's disease, Amyotrophic lateral sclerosis, and multiple sclerosis.

Abstract: The present invention relates to the field of pharmaceutical composition comprising “LIT-TB” derivatives. More particularly it relates to “LIT-TB” derivatives for use in the treatment of neurodegenerative diseases, and more particularly in the treatment of Huntington's disease. The invention also relates to the “LIT-TB” derivatives and preparation thereof.

Abstract: The invention relates to compounds, pyridine derivatives, and pharmaceutical 10 compositions containing same for use in the treatment of pain. It also relates to specific compounds, compositions comprising the same and uses thereof, in particular in the treatment of pain.

Abstract: The present invention is in the field of surfactants to extract a platinum group metal or gold, in particular palladium, from organic compositions. In particular, the invention concerns the use of surfactants to back-extract a platinum group metal or gold, in particular palladium, from organic compositions further comprising an extractant of said platinum group metal or gold, in particular palladium from an aqueous solution.

Abstract: The present invention is in the field of surfactants to extract a platinum group metal or gold, in particular palladium, from organic compositions. In particular, the invention concerns the use of surfactants to back-extract a platinum group metal or gold, in particular palladium, from organic compositions further comprising an extractant of said platinum group metal or gold, in particular palladium from an aqueous solution.

Abstract: The invention pertains to novel FLT3 receptor antagonists of general formula (1). The compounds are useful for the treatment or the prevention of pain disorders, cancer and autoimmune diseases.

Abstract: The invention pertains to novel FLT3 receptor antagonists of general formula (1). The compounds are useful for the treatment or the prevention of pain disorders, cancer and autoimmune diseases.

Abstract: We disclose substances and a process of developing such substances as potent and selective inhibitors of isoforms of phosphodiesterases of types 1 to 5 (PDE1, PDE2, PDE3, PDE4, PDE5) based on two flavonoids: dioclein, floranol and natural or synthetic analogs thereof. They may be associated with cyclodextrins in inclusion complexes or using a biodegradable or non-biodegradable polymer, such as PLGA, PLA, PGA or mixtures thereof in controlled release devices. Their respective pharmaceutical compositions as well as pharmaceutical and pharmacologically acceptable excipients may be used for the study and treatment of cardiovascular diseases and associated products.

Abstract: The present invention concerns compounds derived from quinoline and quinoxaline, their preparation and their uses, particularly in the field of therapeutics and vaccines or for developing active compounds. The inventive compounds are of general formula (I), and their pharmaceutically acceptable salts.

Abstract: The invention concerns the field of synthesis organic chemistry applied to the pharmaceutical field and concerns novel derivatives of 4-hydroxybutanoic acid and its higher homologue, 5-hydroxypentanoic acid, their crotonic homologues, pharmaceutical compositions containing them and their pharmaceutical uses. Said novel derivatives are capable of binding with ?-hydroxybutyrate (GHB)-specific receptors and hence capable of exhibiting agonist or antagonist properties, in particular for treating sleep disorders, anxiety and general diseases of the central nervous system. The invention also concerns compounds of general formula (I) wherein the substituents are as defined in the description.